Literature DB >> 11372690

A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor.

A C Goodeve1, J C Eikenboom, D Ginsburg, L Hilbert, C Mazurier, I R Peake, J E Sadler, F Rodeghiero.   

Abstract

Examination of the entire von Willebrand factor (VWF) gene for mutations, particularly in types 1 and 3 von Willebrand disease (VWD) is becoming more widely practised. The sequence of the entire VWF gene will soon be compiled as a single sequence. For these reasons, a clearly defined nomenclature to use for numbering the VWF nucleotide and amino acid sequence is required. The following recommendations are made for VWF numbering. VWF cDNA nucleotide sequence should be numbered from the A of the initiator ATG as the +1 position. Genomic DNA should be prefixed with a "g" and also numbered from this position. Amino acid (aa) numbering should be from the initiator methionine as the +1 position with sequential numbering of aa throughout VWF. To avoid confusion with previously used numbering schemes for mature VWF, which started from serine 764 of pre-pro VWF, the use of the single letter amino acid code is recommended.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11372690

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Integration of molecular and clinical data of 40 unrelated von Willebrand Disease families in a Spanish locus-specific mutation database: first release including 58 mutations.

Authors:  Irene Corrales; Lorena Ramírez; Júlia Ayats; Carme Altisent; Rafael Parra; Francisco Vidal
Journal:  Haematologica       Date:  2010-08-26       Impact factor: 9.941

2.  Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene.

Authors:  Heidi L Lemmerhirt; Jordan A Shavit; Gallia G Levy; Suzanne M Cole; Jeffrey C Long; David Ginsburg
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

3.  The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Authors:  Bagirath Gangadharan; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

4.  Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.

Authors:  Alessandra Casonato; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Roberto Padrini; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

5.  Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.

Authors:  Maha Othman; Yvette Chirinian; Christine Brown; Colleen Notley; Nicholas Hickson; Daniel Hampshire; Suzanne Buckley; Simon Waddington; Alan L Parker; Andrew Baker; Paula James; David Lillicrap
Journal:  Blood       Date:  2010-08-09       Impact factor: 22.113

6.  An apparently silent nucleotide substitution (c.7056C>T) in the von Willebrand factor gene is responsible for type 1 von Willebrand disease.

Authors:  Viviana Daidone; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Antonella Bertomoro; Antonio Pagnan; Alessandra Casonato
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

7.  Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Authors:  Pier Mannuccio Mannucci; Christine Kempton; Carolyn Millar; Edward Romond; Amy Shapiro; Ingvild Birschmann; Margaret V Ragni; Joan Cox Gill; Thynn Thynn Yee; Robert Klamroth; Wing-Yen Wong; Miranda Chapman; Werner Engl; Peter L Turecek; Tobias M Suiter; Bruce M Ewenstein
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.